Feb 22, 2019 - Teva has shown problems in generating earnings for its investors.My gap analysis shows that Teva is unlikely to recover quickly after the earnings selloff.Teva has high levels of debt, which is concer
Feb 20, 2019 - After showing several years of resilience, competition is finally starting to eat away at Teva’s Copaxone and ProAir revenue.Investors and management expect Ajovy and Austedo to make up much of the lo
Feb 20, 2019 - Names on the move ahead of the open.
Feb 20, 2019 - Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Feb 19, 2019 - Teva Pharmaceutical Industries (NYSE:TEVA) has settled with the Federal Trade Commission to resolve all outstanding litigation. That includes the FTC dropping claims against Teva and affiliates acros
Feb 19, 2019 - The USPTO's Patent Trial and Appeal Board has agreed to review two patents (Nos. 9,340,614 and 9,226,951) covering Teva Pharmaceutical Industries' (TEVA -0.3%) migraine med AJOVY (fremenezumab).Compet
Feb 19, 2019 - Since the acquisition of Actavis, Teva's balance sheet and cash flow were destroyed. It now has focused relentlessly on realigning its strategy and restoring the balance sheet.Halfway through now, it
Feb 19, 2019 - Teva Pharmaceutical Industries Ltd (TEVA) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: TEVA, release date:Feb 19, 2019
Feb 19, 2019 - Teva Pharmaceutical (NYSE:TEVA) expects its generic version of Mylan's (NASDAQ:MYL) EpiPen to have about 25% share of the U.S. market by the end of 2019.The company is already selling its product for
Feb 18, 2019 - Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.